Testing MCLA-129 plus ensartinib for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have an advanced solid tumor (like lung, head and neck, or stomach cancer) that cannot be cured with standard treatments.
- Your tumor has a MET gene change, confirmed by a special lab test.
- You've had prior cancer treatments that stopped working or caused too many side effects.
- You are well enough to be up and about (ECOG score 0 or 1) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
This trial tests a combination of two experimental drugs, Simmitinib and SG001, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to find out if this combination is safe and effective.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This study tests a new drug called MCLA-129 for people with advanced non-small cell lung cancer that has a specific MET gene change (amplification) or who have previously been helped by a MET inhibitor. It is for those whose cancer has stopped responding to standard treatments like EGFR-targeted therapy or chemotherapy.
This trial tests the drug ensartinib in people with advanced solid tumors (not lung cancer) that have an ALK or MET gene change. It may be an option if standard treatments are not working, not tolerated, or refused.
This trial tests a new combination treatment—MCLA-129 plus a targeted pill called Befotertinib—for people with advanced non-small cell lung cancer that has a specific EGFR gene change. It aims to see if the combination works better in patients who either haven't had treatment yet or whose cancer has stopped responding to other EGFR-targeted therapies.
Hear when a new Solid Advanced Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.